← Back to patent-cliff list
Parecoxib Sodium
Tier C — Watch / tradeParecoxib Sodium
Pfizer Inc.
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：COX-2
Brand：Rayzon, Xapit, Dynastat
Indications (approved)：Postoperative pain
Regional status
US
-
EU
Phase II
2025-01-01
China
Approved
2008-03-24
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Parecoxib Sodium?
Approved indications include: Postoperative pain.
When does the Parecoxib Sodium patent expire?
No public expiry year is available for Parecoxib Sodium yet; this page updates once verified.
How do I get a quote for Parecoxib Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27